Boston Scientific reported strong Q2 results with revenue of $5.442 billion and adjusted EPS of $0.86, surpassing analyst expectations. However, RBC Capital lowered the 2026 stock price target from $85 to $70 due to competitive pressures and a reduced earnings forecast for the year. Despite this, analysts remain optimistic about the company's long-term growth prospects, citing an attractive valuation and promising new products like the SEISMIQ 4CE coronary catheter. The stock still shows potential upside from its current price of $44.80 as Boston Scientific focuses on innovation and market expansion.
Boston Scientific reported better-than-expected results for the second quarter, with adjusted earnings per share of $0.86 surpassing the $0.83 estimate and revenue of $5.442 billion beating the $5.37 billion forecast. The company saw a 7.5% increase ...
Boston Scientific reported a 7.5% increase in Q2 2026 net sales to $5.442 billion, surpassing guidance with adjusted EPS of $0.86, up from $0.75 last year. The company completed a $2 billion share repurchase and invested $1.5 billion in MiRus LLC, ga...
Belo Sun Mining Corp. announced the final dismissal of a civil public action filed by Brazil's Federal Public Defender's Office against its Volta Grande Gold Project. The lawsuit, which sought to suspend the project's licensing pending further indige...
